AmtixBio

Infectious fungal diseases are caused by fungi commonly found in human environments such as soil, air, and water. It is estimated that 25% of the global population (approximately 1.7 billion people) is infected with various pathogenic fungi. According to recent results published in The Lancet Infectious Diseases (2024), the number of global fungal infection cases has nearly doubled in the past decade. It is estimated that 6.5 million cases of invasive fungal infections occur annually, with approximately 3.8 million deaths. This represents 6.8% of the approximately 55 million deaths worldwide each year, significantly surpassing deaths from tuberculosis, malaria, hepatitis, and pneumonia. Compared to 16% mortality from heart disease and 11% from cancer and stroke, fungal infections are confirmed to be highly dangerous.

Inflammation is a biological defense response to harmful stimuli, such as pathogens, damaged cells, or irritants that are interpreted as potentially harmful. Microbial infections are a major cause of inflammation. Inflammation after injury or under certain conditions is a normal and healthy response. However, inflammatory disorders that cause the immune system to attack the body's own cells or tissues can lead to abnormal inflammation, posing risks of chronic pain, redness, swelling, induration, and damage.

The biocompatible material SAMH that we are developing is characterized by its ability to form hydrogels via in situ self-crosslinking within the body. This technology serves as a drug delivery system that ensures sustained release and offers diverse drug administration routes. SAMH can be used with a range of drugs, from small molecules to biopharmaceuticals, providing versatility in drug modalities. We formulate the drug into various forms, such as solutions (SAMP-Sol), microparticles (SAMH-MP), or microneedles (SAMH-MN), depending on the drug’s properties and/or target diseases.